IMPACT | Jotup

Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia

Retrieved on:

月曜日, 6月 26, 2023

ACT, Venture round, Mankind Pharma, Lung cancer, Patient, IMPACT, Colorectal cancer, Cachexia, Series, ActiMates, Therapy, Pharmaceutical industry

Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that it has raised over £5 million in an over-subscribed Series A financing round.

Key Points:

Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that it has raised over £5 million in an over-subscribed Series A financing round.
This investment will support the development of the Actimed pipeline, including S-pindolol benzoate, with preparations under way for a Phase 2b/3 programme (the “IMPACT” programme) targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.
Proceeds from the financing will be used to further advance the Actimed development portfolio, notably its lead asset S-pindolol benzoate.
Earlier this year, Actimed launched a Series B financing round aimed at funding the IMPACT programme to completion.

Seismic Therapeutic Announces Presentation of Preclinical Data for Advancing Novel Biologics Drug Programs at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies

Retrieved on:

水曜日, 6月 14, 2023

Biotechnology, General Health, Other Health, Health, Pharmaceutical, Autoimmune disease, Enzyme, Immunology, Therapy, Senior, Seismology, Doctor of Philosophy, Federation, IMPACT, Machine learning, DCB, Poster, Vaccine, Flour

Seismic Therapeutic, Inc. , the machine learning immunology company, today announced nine poster presentations supporting the company’s emerging pipeline of novel biologics derived from its proprietary IMPACT platform to treat autoimmune diseases at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) taking place on June 20-23 in Boston, MA.

Key Points:

Seismic Therapeutic, Inc. , the machine learning immunology company, today announced nine poster presentations supporting the company’s emerging pipeline of novel biologics derived from its proprietary IMPACT platform to treat autoimmune diseases at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) taking place on June 20-23 in Boston, MA.
“We are thrilled to share preclinical data showing rapid advancement of our Ig sculpting enzymes and DcB antibody programs and highlighting the translational immunology capabilities within our IMPACT platform,” said Kevin Otipoby, PhD, Senior VP Immunology of Seismic Therapeutic.
The Promise of Machine Learning: Using Seismic’s IMPACT Platform to Design IgG Cleaving Enzymes for Chronic Treatment of Autoimmune Diseases
Tuesday, June 20th 6:00 - 7:45 p.m.
Tuesday, June 20th 6:00 - 7:45 p.m.
Tuesday, June 20th 6:00 - 7:45 p.m.
In addition to the poster presentations, Ivan Mascanfroni, PhD, Senior Director of Immunology at Seismic, will chair the “Adaptive Immunity” session on Friday, June 23rd at 8 a.m.

Forter Announces IMPACT 2023

Retrieved on:

水曜日, 6月 14, 2023

Learning, PwC, Breakout (Miley Cyrus song), PacSun, Trust, Intelligence, Total Wine & More, Capital One, Restaurant Brands International, Trusted Platform Module, IMPACT, HelloFresh, Hearing, Digital, Adidas, Online shopping, NEW YORK

NEW YORK, June 14, 2023 /PRNewswire/ -- Forter, the Trust Platform for digital commerce, today announced its industry conference IMPACT 2023 will take place on Wednesday, October 11 in New York City, featuring speakers from adidas, HelloFresh, PwC, Total Wine & More and others.

Key Points:

Speakers include leaders from adidas, HelloFresh, PwC and Total Wine & More
NEW YORK, June 14, 2023 /PRNewswire/ -- Forter , the Trust Platform for digital commerce, today announced its industry conference IMPACT 2023 will take place on Wednesday, October 11 in New York City, featuring speakers from adidas, HelloFresh, PwC, Total Wine & More and others.
Now in its second year, IMPACT 2023 creates the space digital commerce leaders have been asking for — a forum to connect, share best practices and hear how peers build great experiences across the customer journey.
"At IMPACT 2023, I'm really looking forward to hearing about other leaders' successes, lessons learned and ideas for what's to come."
For more information and to register for IMPACT 2023, visit http://forter.com/impact .

IMPACT Community Capital Showcases Firm’s 25-Year History of Impact Investing in Third Annual Impact Report

Retrieved on:

水曜日, 6月 7, 2023

IMPACT Community Capital (“IMPACT”) today released a special 25th Anniversary edition of its annual impact report, entitled “25 Years of IMPACT.” In the report, IMPACT – an investment manager with a track record of investing more than $2.4 billion for impact in affordable housing, childcare, and healthcare – highlights the firm’s history over the last quarter century and its future vision for investing in communities of opportunity.

Key Points:

IMPACT Community Capital (“IMPACT”) today released a special 25th Anniversary edition of its annual impact report, entitled “25 Years of IMPACT.” In the report, IMPACT – an investment manager with a track record of investing more than $2.4 billion for impact in affordable housing, childcare, and healthcare – highlights the firm’s history over the last quarter century and its future vision for investing in communities of opportunity.
“We were investing for impact long before anyone called it ‘impact investing,’” said Jeff Brenner, President and CEO of IMPACT.
We have demonstrated what is possible, and we are ready to do far more.”
To view the full 2023 Impact Report, “25 Years of IMPACT,” download here .
To learn more about the milestones that have made IMPACT a pioneering impact investing leader over the past quarter century, visit the firm’s special 25th Anniversary webpage and explore its “Moments of IMPACT.”

EPOS Launches New IMPACT 1000 Bluetooth Headset Series

Retrieved on:

木曜日, 6月 1, 2023

Microsoft Teams, OpenOffice, ANC, Communication, Speech, Red Dot, Philadelphia Daily News Open, Microsoft, Brain, Element, Movement, Science, IMPACT, Machine learning, Environment, EPOS, Mobile phone, Cassette tape, Telescopic sight

COPENHAGEN, Denmark, June 1, 2023 /PRNewswire/ -- EPOS, the global audio brand, today announces that the IMPACT 1000, an on-ear, future-proof Bluetooth® headset, is available for purchase. Designed for professionals who value clear communication, the IMPACT 1000 ensures all meeting participants can stay focused - even in noisy environments.

Key Points:

COPENHAGEN, Denmark, June 1, 2023 /PRNewswire/ -- EPOS, the global audio brand, today announces that the IMPACT 1000, an on-ear, future-proof Bluetooth® headset, is available for purchase.
Designed for professionals who value clear communication, the IMPACT 1000 ensures all meeting participants can stay focused - even in noisy environments.
Leveraging insights such as these, EPOS develops machine learning technologies such as those in the IMPACT 1000 to help end-users' brains better process and understand audio stimuli.
IMPACT 1000 features EPOS BrainAdapt™ technology to reduce brain fatigue with hybrid adaptive Active Noise Cancellation (ANC) and industry-leading voice pickup powered by EPOS AI™.

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

Retrieved on:

木曜日, 6月 1, 2023

DNA, Partnership, Therapy, Neoplasm, Biotechnology, PARP1, DNA repair, Patient, IMPACT, Engineering, Eikon, Chairperson, Pharmaceutical industry, Impact

Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan).

Key Points:

Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan).
"We are delighted to establish the global partnership with Eikon, whose leadership team has a well-documented track record of developing some of the world's most therapeutically meaningful and commercially successful oncology medicines."
We look forward to working with Eikon in bringing new cancer medicines to patients in China and across the globe."
Eikon is delighted to partner with Impact scientists to help develop IMP1734 and other selective PARP1 inhibitors that exploit DNA damage response aberrations often found in tumors to selectively kill cancer cells," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics.

CyberArk Announces Identity Security Impact Customer Award Winners

Retrieved on:

水曜日, 5月 31, 2023

Data Management, Online Privacy, Security, Technology, Software, Networks, Internet, CYBR, Aflac, Identity, Part, Massive, IMPACT, Levels of identity security, Digital transformation, Risk, Online shopping, CyberArk

CyberArk (NASDAQ: CYBR ), the Identity Security company, announced its first-ever CyberArk Identity Security Impact Award winners at CyberArk IMPACT 23.

Key Points:

CyberArk (NASDAQ: CYBR ), the Identity Security company, announced its first-ever CyberArk Identity Security Impact Award winners at CyberArk IMPACT 23.
“I want to thank those who submitted such great examples of how CyberArk Identity Security solutions are helping drive business impact and unparalleled operational efficiency.
Winners were announced on stage at IMPACT 23, the largest Identity Security event in the world.
The 2023 Identity Security Impact winners are:
Using CyberArk as Part of a Massive Digital Transformation Initiative: Aflac
Using CyberArk to Drive Business Impact: Citigroup
Demonstrating a Massive Cyber Risk Reduction with CyberArk: Maximus
Moving Closer and Closer to Zero Trust with CyberArk: Pacific Dental Services

CyberArk Supercharges Identity Security Platform with Automation and Artificial Intelligence Innovations

Retrieved on:

火曜日, 5月 23, 2023

CyberArk IMPACT 23 -- CyberArk (NASDAQ: CYBR ), the Identity Security company, today announced new products and features across the CyberArk Identity Security Platform, making it the most powerful platform of its kind.

Key Points:

CyberArk IMPACT 23 -- CyberArk (NASDAQ: CYBR ), the Identity Security company, today announced new products and features across the CyberArk Identity Security Platform, making it the most powerful platform of its kind.
CyberArk leads the market with innovative new features and investments in automation and artificial intelligence to improve Identity Security and enable organizations to implement proactive controls and defensive strategies.
Enhancements across the CyberArk Identity Security Platform focus on further improving security, adoption and user experience.
In addition, at IMPACT 23 CyberArk also announced CyberArk Secure Browser , a first-of-its-kind Identity Security web browser.

CyberArk to Host Investor Track at IMPACT 23: The Identity Security Conference

Retrieved on:

木曜日, 5月 18, 2023

Data Management, Security, Technology, Software, Networks, Internet, CYBR, Hynes Convention Center, Webcast, IMPACT, Keynote, Nightclub, Cryptocurrency, CyberArk, Levels of identity security

CyberArk (NASDAQ: CYBR ), the global leader in Identity Security , today announced that it will host an Investor Track during CyberArk IMPACT 23 , the company’s annual conference dedicated to strategies and technologies for defending against identity-based cyberattacks.

Key Points:

CyberArk (NASDAQ: CYBR ), the global leader in Identity Security , today announced that it will host an Investor Track during CyberArk IMPACT 23 , the company’s annual conference dedicated to strategies and technologies for defending against identity-based cyberattacks.
Members of CyberArk’s executive team will discuss our leadership position in Identity Security, our innovation roadmap, as well as market dynamics and our go-to-market approach.
The Investor Track will take place at the Hynes Convention Center in Boston on May 23 beginning at 1:30 p.m. Eastern Time.
The Investor Track will be webcast live via the “Investor Relations” section of the company’s website at www.cyberark.com .

Seismic Therapeutic Announces Presentation of Preclinical Data Demonstrating Advances in Novel Biologics Discovery at the PEGS Boston Summit

Retrieved on:

木曜日, 5月 11, 2023

Biotechnology, General Health, Other Health, Health, Pharmaceutical, Epitope, Enzyme, DCB, Poster, Boston, Therapy, Senior, IMPACT, Doctor of Philosophy, Vaccine

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data that describe the application of the company’s IMPACT platform at PEGS Boston 2023, taking place on May 15-19.

Key Points:

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data that describe the application of the company’s IMPACT platform at PEGS Boston 2023, taking place on May 15-19.
The three poster presentations outline how Seismic’s IMPACT platform enables the parallel optimization of multiple parameters, including predicting and removing B and T cell epitopes, augmenting drug-like properties and retaining protein function, to create novel drug candidates across the immunoglobin (Ig) sculpting enzymes and dual-cell bidirectional (DcB) antibody product areas.
Seismic is designing novel biologics derived from the IMPACT platform to address unmet medical needs for diseases involving humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system.
“We are pleased to share the advancements of our efforts in biologics discovery uniquely enabled by our IMPACT platform,” said Nathan Higginson-Scott, PhD, Chief Technology Officer and Senior VP Drug Creation of Seismic Therapeutic.